KRSA Cyclerion Therapeutics | $30.72 +0.8% | 10/5/2026 | | Initiated Coverage | $44.00 | Outperform | 00.00% | View details for Wedbush rating of Cyclerion Therapeutics (NASDAQ:KRSA) on 10/5/2026 |
STTK Shattuck Labs | $6.50 -3.4% | 10/2/2026 | | Boost Price Target | $11.00 ➝ $14.00 | Outperform | 00.00% | View details for Wedbush rating of Shattuck Labs (NASDAQ:STTK) on 10/2/2026 |
WVE WAVE Life Sciences | $3.75 -0.8% | 10/2/2026 | | Set Price Target | $13.00 | | 00.00% | View details for Wedbush rating of WAVE Life Sciences (NASDAQ:WVE) on 10/2/2026 |
LQDA Liquidia | $27.64 -3.5% | 10/2/2026 | | Set Price Target | $58.00 | | 00.00% | View details for Wedbush rating of Liquidia (NASDAQ:LQDA) on 10/2/2026 |
FHTX Foghorn Therapeutics | $2.00 -1.0% | 10/2/2026 | | Downgrade | $10.00 ➝ $2.00 | Outperform ➝ Neutral | 00.00% | View details for Wedbush rating of Foghorn Therapeutics (NASDAQ:FHTX) on 10/2/2026 |
AKTS Aktis Oncology | $18.52
| 10/2/2026 | | Reiterated Rating | $35.00 | Outperform | 00.00% | View details for Wedbush rating of Aktis Oncology (NASDAQ:AKTS) on 10/2/2026 |
CTSH Cognizant Technology Solutions | $58.17 -0.6% | 10/2/2026 | | Reiterated Rating | $70.00 | Outperform | 00.00% | View details for Wedbush rating of Cognizant Technology Solutions (NASDAQ:CTSH) on 10/2/2026 |
JBIO Jade Biosciences | $14.07 -0.4% | 10/1/2026 | | Reiterated Rating | $47.00 | Outperform | 00.00% | View details for Wedbush rating of Jade Biosciences (NASDAQ:JBIO) on 10/1/2026 |
RCUS Arcus Biosciences | $24.73 +1.2% | 9/30/2026 | | Reiterated Rating | $43.00 | Outperform | 00.00% | View details for Wedbush rating of Arcus Biosciences (NYSE:RCUS) on 9/30/2026 |
ZBIO Zenas BioPharma | $27.83 -1.7% | 9/30/2026 | | Reiterated Rating | $45.00 | Outperform | 00.00% | View details for Wedbush rating of Zenas BioPharma (NASDAQ:ZBIO) on 9/30/2026 |
Get the Latest News and Ratings for Your Stocks Enter your email address below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter.
|
DMRA Damora Therapeutics, Inc. Common Stock | $20.22 -2.1% | 9/29/2026 | | Reiterated Rating | $40.00 | Outperform | 00.00% | View details for Wedbush rating of Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) on 9/29/2026 |
ACET Adicet Bio | $6.47 -0.5% | 9/28/2026 | | Reiterated Rating | $25.00 ➝ $28.00 | Outperform | 00.00% | View details for Wedbush rating of Adicet Bio (NASDAQ:ACET) on 9/28/2026 |
MU Micron Technology | $1,062.88 -1.1% | 9/28/2026 | | Reiterated Rating | $1,400.00 | Outperform | 00.00% | View details for Wedbush rating of Micron Technology (NASDAQ:MU) on 9/28/2026 |
ZS Zscaler | $201.80 +2.6% | 9/28/2026 | | Reiterated Rating | $215.00 | Outperform | 00.00% | View details for Wedbush rating of Zscaler (NASDAQ:ZS) on 9/28/2026 |
ORKA Oruka Therapeutics | $84.38 -0.2% | 9/24/2026 | | Set Price Target | $120.00 | | 00.00% | View details for Wedbush rating of Oruka Therapeutics (NASDAQ:ORKA) on 9/24/2026 |
EPRX Eupraxia Pharmaceuticals | $7.74 +6.9% | 9/24/2026 | | Initiated Coverage | $17.00 | Outperform | 00.00% | View details for Wedbush rating of Eupraxia Pharmaceuticals (NASDAQ:EPRX) on 9/24/2026 |
ORKA Oruka Therapeutics | $84.38 -0.2% | 9/24/2026 | | Reiterated Rating | $165.00 | Outperform | 00.00% | View details for Wedbush rating of Oruka Therapeutics (NASDAQ:ORKA) on 9/24/2026 |
P Everpure | $143.87 +2.7% | 9/24/2026 | | Reiterated Rating | $130.00 | Outperform | 00.00% | View details for Wedbush rating of Everpure (NYSE:P) on 9/24/2026 |
ROKU Roku | $153.41 +0.7% | 9/24/2026 | | Reiterated Rating | $155.00 | Neutral | 00.00% | View details for Wedbush rating of Roku (NASDAQ:ROKU) on 9/24/2026 |
CMPX Compass Therapeutics | $0.96 +12.1% | 9/23/2026 | | Set Price Target | $4.00 | | 00.00% | View details for Wedbush rating of Compass Therapeutics (NASDAQ:CMPX) on 9/23/2026 |
MAZE Maze Therapeutics | $26.43
| 9/23/2026 | | Reiterated Rating | $48.00 | Outperform | 00.00% | View details for Wedbush rating of Maze Therapeutics (NASDAQ:MAZE) on 9/23/2026 |
NKTR Nektar Therapeutics | $42.22 -3.1% | 9/23/2026 | | Lower Price Target | $80.00 ➝ $50.00 | Neutral | 00.00% | View details for Wedbush rating of Nektar Therapeutics (NASDAQ:NKTR) on 9/23/2026 |
SHOP Shopify | $160.11 +5.8% | 9/23/2026 | | Reiterated Rating | $176.00 | Outperform | 00.00% | View details for Wedbush rating of Shopify (NASDAQ:SHOP) on 9/23/2026 |
TLX Telix Pharmaceuticals | $10.88 +3.1% | 9/23/2026 | | Reiterated Rating | $22.00 | Outperform | 00.00% | View details for Wedbush rating of Telix Pharmaceuticals (NASDAQ:TLX) on 9/23/2026 |
WLDN Willdan Group | $73.58 +0.1% | 9/23/2026 | | Reiterated Rating | $130.00 | Outperform | 00.00% | View details for Wedbush rating of Willdan Group (NASDAQ:WLDN) on 9/23/2026 |
CMPX Compass Therapeutics | $0.96 +12.1% | 9/22/2026 | | Downgrade | $5.00 ➝ $1.00 | Outperform ➝ Neutral | 00.00% | View details for Wedbush rating of Compass Therapeutics (NASDAQ:CMPX) on 9/22/2026 |
ABVX Abivax | $91.73 -1.2% | 9/22/2026 | | Lower Price Target | $140.00 ➝ $118.00 | Neutral | 00.00% | View details for Wedbush rating of Abivax (NASDAQ:ABVX) on 9/22/2026 |
IONQ IonQ | $43.04 -1.7% | 9/22/2026 | | Reiterated Rating | $75.00 | Outperform | 00.00% | View details for Wedbush rating of IonQ (NYSE:IONQ) on 9/22/2026 |
TVTX Travere Therapeutics | $57.67 +1.3% | 9/22/2026 | | Reiterated Rating | $76.00 | Outperform | 00.00% | View details for Wedbush rating of Travere Therapeutics (NASDAQ:TVTX) on 9/22/2026 |
FUBO fuboTV | $8.60 -0.7% | 9/18/2026 | | Reiterated Rating | $19.00 | Outperform | 00.00% | View details for Wedbush rating of fuboTV (NYSE:FUBO) on 9/18/2026 |
XENE Xenon Pharmaceuticals | $37.57 -1.2% | 9/18/2026 | | Lower Price Target | $71.00 ➝ $55.00 | Outperform | 00.00% | View details for Wedbush rating of Xenon Pharmaceuticals (NASDAQ:XENE) on 9/18/2026 |
COGT Cogent Biosciences | $30.87 -0.5% | 9/16/2026 | | Reiterated Rating | $55.00 | Outperform | 00.00% | View details for Wedbush rating of Cogent Biosciences (NASDAQ:COGT) on 9/16/2026 |
NUVB Nuvation Bio | $4.97 -3.4% | 9/16/2026 | | Reiterated Rating | $11.00 | Outperform | 00.00% | View details for Wedbush rating of Nuvation Bio (NYSE:NUVB) on 9/16/2026 |
RCKT Rocket Pharmaceuticals | $2.61 +2.0% | 9/16/2026 | | Reiterated Rating | $15.00 | Outperform | 00.00% | View details for Wedbush rating of Rocket Pharmaceuticals (NASDAQ:RCKT) on 9/16/2026 |
SRRK Scholar Rock | $43.40 -7.3% | 9/15/2026 | | Reiterated Rating | $64.00 | Outperform | 00.00% | View details for Wedbush rating of Scholar Rock (NASDAQ:SRRK) on 9/15/2026 |
BNTC Benitec Biopharma | $9.23 +2.8% | 9/15/2026 | | Boost Price Target | $16.00 ➝ $17.00 | Outperform | 00.00% | View details for Wedbush rating of Benitec Biopharma (NASDAQ:BNTC) on 9/15/2026 |
CATX Perspective Therapeutics | $2.57 -6.9% | 9/15/2026 | | Reiterated Rating | $11.00 | Outperform | 00.00% | View details for Wedbush rating of Perspective Therapeutics (NYSEAMERICAN:CATX) on 9/15/2026 |
SION Sionna Therapeutics | $4.85 -1.2% | 9/15/2026 | | Boost Price Target | $5.00 ➝ $6.00 | Neutral | 00.00% | View details for Wedbush rating of Sionna Therapeutics (NASDAQ:SION) on 9/15/2026 |
CBIO Crescent Biopharma | $13.94 -2.7% | 9/14/2026 | | Reiterated Rating | $27.00 | Outperform | 00.00% | View details for Wedbush rating of Crescent Biopharma (NASDAQ:CBIO) on 9/14/2026 |
RBLX Roblox | $44.51 +0.9% | 9/14/2026 | | Boost Price Target | $40.00 ➝ $48.00 | Neutral | 00.00% | View details for Wedbush rating of Roblox (NYSE:RBLX) on 9/14/2026 |
Feds Say Your Cash Isn’t Property—Can They Take It? (Ad) The Department of Justice recently argued in court that cash may not qualify as legal property.
That raises new questions about how protected everyday bank accounts and retirement savings really are. Get the free information kit with 3 strategies to help protect your savings |
SRRK Scholar Rock | $43.40 -7.3% | 9/14/2026 | | Reiterated Rating | $64.00 | Outperform | 00.00% | View details for Wedbush rating of Scholar Rock (NASDAQ:SRRK) on 9/14/2026 |
TLX Telix Pharmaceuticals | $10.88 +3.1% | 9/14/2026 | | Reiterated Rating | $22.00 | Outperform | 00.00% | View details for Wedbush rating of Telix Pharmaceuticals (NASDAQ:TLX) on 9/14/2026 |
META Meta Platforms | $741.90 +1.9% | 9/11/2026 | | Boost Price Target | $595.00 ➝ $650.00 | Neutral | 00.00% | View details for Wedbush rating of Meta Platforms (NASDAQ:META) on 9/11/2026 |
CRWD CrowdStrike | $272.67 +1.0% | 9/11/2026 | | Reiterated Rating | $250.00 | Outperform | 00.00% | View details for Wedbush rating of CrowdStrike (NASDAQ:CRWD) on 9/11/2026 |
DDOG Datadog | $276.42 -0.3% | 9/11/2026 | | Initiated Coverage | $260.00 ➝ $275.00 | Outperform | 00.00% | View details for Wedbush rating of Datadog (NASDAQ:DDOG) on 9/11/2026 |
ESTC Elastic | $95.11 +1.2% | 9/11/2026 | | Initiated Coverage | $125.00 | Outperform | 00.00% | View details for Wedbush rating of Elastic (NYSE:ESTC) on 9/11/2026 |
PANW Palo Alto Networks | $406.76 +0.9% | 9/11/2026 | | Initiated Coverage | $400.00 | Outperform | 00.00% | View details for Wedbush rating of Palo Alto Networks (NASDAQ:PANW) on 9/11/2026 |
RBRK Rubrik | $122.80 +3.6% | 9/11/2026 | | Initiated Coverage | $90.00 ➝ $120.00 | Outperform | 00.00% | View details for Wedbush rating of Rubrik (NYSE:RBRK) on 9/11/2026 |
S SentinelOne | $25.44 +1.5% | 9/11/2026 | | Initiated Coverage | $25.00 | Outperform | 00.00% | View details for Wedbush rating of SentinelOne (NYSE:S) on 9/11/2026 |
VRNS Varonis Systems | $48.15 +1.2% | 9/11/2026 | | Reiterated Rating | $46.00 | Outperform ➝ Neutral | 00.00% | View details for Wedbush rating of Varonis Systems (NASDAQ:VRNS) on 9/11/2026 |
ZS Zscaler | $201.80 +2.6% | 9/11/2026 | | Initiated Coverage | $215.00 | Outperform | 00.00% | View details for Wedbush rating of Zscaler (NASDAQ:ZS) on 9/11/2026 |
QLYS Qualys | $198.68 +2.9% | 9/10/2026 | | Downgrade | $175.00 | Outperform ➝ Neutral | 00.00% | View details for Wedbush rating of Qualys (NASDAQ:QLYS) on 9/10/2026 |
TLS Telos | $4.43 +5.7% | 9/10/2026 | | Downgrade | $5.00 | Outperform ➝ Neutral | 00.00% | View details for Wedbush rating of Telos (NASDAQ:TLS) on 9/10/2026 |
DT Dynatrace | $60.31 +1.7% | 9/10/2026 | | Downgrade | $54.00 | Outperform ➝ Neutral | 00.00% | View details for Wedbush rating of Dynatrace (NYSE:DT) on 9/10/2026 |
CHKP Check Point Software Technologies | $129.58 -0.6% | 9/10/2026 | | Downgrade | $135.00 | Outperform ➝ Neutral | 00.00% | View details for Wedbush rating of Check Point Software Technologies (NASDAQ:CHKP) on 9/10/2026 |
TENB Tenable | $38.51 +4.5% | 9/10/2026 | | Downgrade | $29.00 | Outperform ➝ Underperform | 00.00% | View details for Wedbush rating of Tenable (NASDAQ:TENB) on 9/10/2026 |
PYXS Pyxis Oncology | $2.24 +4.7% | 9/10/2026 | | Boost Price Target | $6.00 ➝ $8.00 | Outperform | 00.00% | View details for Wedbush rating of Pyxis Oncology (NASDAQ:PYXS) on 9/10/2026 |
DDOG Datadog | $276.42 -0.3% | 9/10/2026 | | Upgrade | | Strong-Buy | 00.00% | View details for Wedbush rating of Datadog (NASDAQ:DDOG) on 9/10/2026 |
DT Dynatrace | $60.31 +1.7% | 9/10/2026 | | Upgrade | | Hold | 00.00% | View details for Wedbush rating of Dynatrace (NYSE:DT) on 9/10/2026 |
IMUX Immunic | $8.07 +1.4% | 9/10/2026 | | Reiterated Rating | $45.00 | Outperform | 00.00% | View details for Wedbush rating of Immunic (NASDAQ:IMUX) on 9/10/2026 |
IRD Opus Genetics | $4.38 -4.4% | 9/10/2026 | | Boost Price Target | $10.00 ➝ $13.00 | Outperform | 00.00% | View details for Wedbush rating of Opus Genetics (NASDAQ:IRD) on 9/10/2026 |
IRON Disc Medicine | $63.33 -1.8% | 9/10/2026 | | Reiterated Rating | $100.00 | Outperform | 00.00% | View details for Wedbush rating of Disc Medicine (NASDAQ:IRON) on 9/10/2026 |
QLYS Qualys | $198.68 +2.9% | 9/10/2026 | | Upgrade | | Hold | 00.00% | View details for Wedbush rating of Qualys (NASDAQ:QLYS) on 9/10/2026 |
TENB Tenable | $38.51 +4.5% | 9/10/2026 | | Upgrade | | Strong Sell | 00.00% | View details for Wedbush rating of Tenable (NASDAQ:TENB) on 9/10/2026 |
TLS Telos | $4.43 +5.7% | 9/10/2026 | | Upgrade | | Hold | 00.00% | View details for Wedbush rating of Telos (NASDAQ:TLS) on 9/10/2026 |
TYRA Tyra Biosciences | $20.93 +2.4% | 9/10/2026 | | Reiterated Rating | $53.00 | Outperform | 00.00% | View details for Wedbush rating of Tyra Biosciences (NASDAQ:TYRA) on 9/10/2026 |
VRNS Varonis Systems | $48.15 +1.2% | 9/10/2026 | | Upgrade | | Hold | 00.00% | View details for Wedbush rating of Varonis Systems (NASDAQ:VRNS) on 9/10/2026 |
PHVS Pharvaris | $30.49 -2.2% | 9/9/2026 | | Boost Price Target | $42.00 ➝ $50.00 | Outperform | 00.00% | View details for Wedbush rating of Pharvaris (NASDAQ:PHVS) on 9/9/2026 |
BBOT BridgeBio Oncology Therapeutics | $3.60 -7.5% | 9/9/2026 | | Reiterated Rating | $25.00 | Outperform | 00.00% | View details for Wedbush rating of BridgeBio Oncology Therapeutics (NASDAQ:BBOT) on 9/9/2026 |
BEAM Beam Therapeutics | $25.67 +4.8% | 9/9/2026 | | Reiterated Rating | $65.00 | Outperform | 00.00% | View details for Wedbush rating of Beam Therapeutics (NASDAQ:BEAM) on 9/9/2026 |
GLUE Monte Rosa Therapeutics | $10.27 -2.2% | 9/9/2026 | | Reiterated Rating | $27.00 | Outperform | 00.00% | View details for Wedbush rating of Monte Rosa Therapeutics (NASDAQ:GLUE) on 9/9/2026 |
NTLA Intellia Therapeutics | $12.75 +4.0% | 9/9/2026 | | Boost Price Target | $12.00 ➝ $13.00 | Neutral | 00.00% | View details for Wedbush rating of Intellia Therapeutics (NASDAQ:NTLA) on 9/9/2026 |
SYRE Spyre Therapeutics | $92.72 -0.5% | 9/9/2026 | | Reiterated Rating | $123.00 | Outperform | 00.00% | View details for Wedbush rating of Spyre Therapeutics (NASDAQ:SYRE) on 9/9/2026 |
PHVS Pharvaris | $30.49 -2.2% | 9/8/2026 | | Reiterated Rating | $42.00 | Outperform | 00.00% | View details for Wedbush rating of Pharvaris (NASDAQ:PHVS) on 9/8/2026 |
UBER Uber Technologies | $69.44 +2.0% | 9/8/2026 | | Reiterated Rating | $91.00 | Outperform | 00.00% | View details for Wedbush rating of Uber Technologies (NYSE:UBER) on 9/8/2026 |
ARGX argenex | $912.87 -0.7% | 9/3/2026 | | Reiterated Rating | $1,150.00 | Outperform | 00.00% | View details for Wedbush rating of argenex (NASDAQ:ARGX) on 9/3/2026 |
NTAP NetApp | $223.77 -1.1% | 9/3/2026 | | Boost Price Target | $150.00 ➝ $170.00 | Neutral | 00.00% | View details for Wedbush rating of NetApp (NASDAQ:NTAP) on 9/3/2026 |
RARE Ultragenyx Pharmaceutical | $14.50 -4.7% | 9/3/2026 | | Lower Price Target | $30.00 ➝ $23.00 | Neutral | 00.00% | View details for Wedbush rating of Ultragenyx Pharmaceutical (NASDAQ:RARE) on 9/3/2026 |
TCRX TScan Therapeutics | $0.30 -7.9% | 9/2/2026 | | Downgrade | $1.00 | Buy ➝ Neutral | 00.00% | View details for Wedbush rating of TScan Therapeutics (NASDAQ:TCRX) on 9/2/2026 |
IRON Disc Medicine | $63.33 -1.8% | 9/2/2026 | | Boost Price Target | $88.00 ➝ $100.00 | Outperform | 00.00% | View details for Wedbush rating of Disc Medicine (NASDAQ:IRON) on 9/2/2026 |
ASND Ascendis Pharma A/S | $228.03 +0.1% | 9/1/2026 | | Reiterated Rating | $327.00 | Outperform | 00.00% | View details for Wedbush rating of Ascendis Pharma A/S (NASDAQ:ASND) on 9/1/2026 |
META Meta Platforms | $741.90 +1.9% | 9/1/2026 | | Reiterated Rating | $595.00 | Neutral | 00.00% | View details for Wedbush rating of Meta Platforms (NASDAQ:META) on 9/1/2026 |
VRSN VeriSign | $292.26 +1.4% | 9/1/2026 | | Boost Price Target | $324.00 ➝ $341.00 | Outperform | 00.00% | View details for Wedbush rating of VeriSign (NASDAQ:VRSN) on 9/1/2026 |
CBIO Crescent Biopharma | $13.94 -2.7% | 8/27/2026 | | Reiterated Rating | $27.00 | Outperform | 00.00% | View details for Wedbush rating of Crescent Biopharma (NASDAQ:CBIO) on 8/27/2026 |
NVDA NVIDIA | $238.90 +2.1% | 8/27/2026 | | Boost Price Target | $330.00 ➝ $345.00 | Outperform | 00.00% | View details for Wedbush rating of NVIDIA (NASDAQ:NVDA) on 8/27/2026 |
P Everpure | $143.87 +2.7% | 8/27/2026 | | Boost Price Target | $127.00 ➝ $130.00 | Outperform | 00.00% | View details for Wedbush rating of Everpure (NYSE:P) on 8/27/2026 |
RVMD Revolution Medicines | $207.68 +0.5% | 8/27/2026 | | Boost Price Target | $201.00 ➝ $225.00 | Outperform | 00.00% | View details for Wedbush rating of Revolution Medicines (NASDAQ:RVMD) on 8/27/2026 |
SYRE Spyre Therapeutics | $92.72 -0.5% | 8/26/2026 | | Lower Price Target | $130.00 ➝ $123.00 | Outperform | 00.00% | View details for Wedbush rating of Spyre Therapeutics (NASDAQ:SYRE) on 8/26/2026 |
BBY Best Buy | $87.42 -0.6% | 8/24/2026 | | Reiterated Rating | | Buy | 00.00% | View details for Wedbush rating of Best Buy (NYSE:BBY) on 8/24/2026 |
SRRK Scholar Rock | $43.40 -7.3% | 8/21/2026 | | Reiterated Rating | $64.00 | Outperform | 00.00% | View details for Wedbush rating of Scholar Rock (NASDAQ:SRRK) on 8/21/2026 |
Why The Biggest Names in AI Are Heading To The Arctic (Ad) Google contracted over 12 GW of energy last year and just announced a 15 billion dollar AI infrastructure investment in Finland. Cerebras followed with plans for a 165 MW data center worth up to 1.7 billion euros.
One small Nasdaq-listed company built its Nordic footprint before this wave hit, with up to 190 MW of capacity approaching ready-for-service status in 2027 to early 2028. Recent long-term data center deals have valued capacity at 1.7 to 2 million dollars per MW annually.
See why this overlooked company could be next in the AI infrastructure spotlight. See why this overlooked company could be next in the spotlight |
P Everpure | $143.87 +2.7% | 8/21/2026 | | Boost Price Target | $105.00 ➝ $127.00 | Outperform | 00.00% | View details for Wedbush rating of Everpure (NYSE:P) on 8/21/2026 |
DASH DoorDash | $191.77 +1.4% | 8/20/2026 | | Boost Price Target | $205.00 ➝ $220.00 | Neutral | 00.00% | View details for Wedbush rating of DoorDash (NASDAQ:DASH) on 8/20/2026 |
WIX Wix.com | $74.06 +2.0% | 8/20/2026 | | Boost Price Target | $55.00 ➝ $80.00 | Neutral | 00.00% | View details for Wedbush rating of Wix.com (NASDAQ:WIX) on 8/20/2026 |
DUOL Duolingo | $147.10 +2.0% | 8/20/2026 | | Boost Price Target | $139.00 ➝ $150.00 | Neutral | 00.00% | View details for Wedbush rating of Duolingo (NASDAQ:DUOL) on 8/20/2026 |
EXPE Expedia Group | $260.17 -1.8% | 8/20/2026 | | Boost Price Target | $334.00 ➝ $417.00 | Outperform | 00.00% | View details for Wedbush rating of Expedia Group (NASDAQ:EXPE) on 8/20/2026 |
EBAY eBay | $107.14 +0.7% | 8/20/2026 | | Boost Price Target | $135.00 ➝ $137.00 | Outperform | 00.00% | View details for Wedbush rating of eBay (NASDAQ:EBAY) on 8/20/2026 |
CRTO Criteo | $14.50 -1.6% | 8/20/2026 | | Lower Price Target | $30.00 ➝ $25.00 | Outperform | 00.00% | View details for Wedbush rating of Criteo (NASDAQ:CRTO) on 8/20/2026 |
TLX Telix Pharmaceuticals | $10.88 +3.1% | 8/20/2026 | | Reiterated Rating | $22.00 | Outperform | 00.00% | View details for Wedbush rating of Telix Pharmaceuticals (NASDAQ:TLX) on 8/20/2026 |
AKTS Aktis Oncology | $18.52
| 8/19/2026 | | Initiated Coverage | $35.00 | Outperform | 00.00% | View details for Wedbush rating of Aktis Oncology (NASDAQ:AKTS) on 8/19/2026 |
CLYM Climb Bio | $11.05 +1.0% | 8/19/2026 | | Reiterated Rating | $20.00 | Outperform | 00.00% | View details for Wedbush rating of Climb Bio (NASDAQ:CLYM) on 8/19/2026 |